[go: up one dir, main page]

MX2017004695A - Formación de imágenes por irm de placas amiloides usando liposomas. - Google Patents

Formación de imágenes por irm de placas amiloides usando liposomas.

Info

Publication number
MX2017004695A
MX2017004695A MX2017004695A MX2017004695A MX2017004695A MX 2017004695 A MX2017004695 A MX 2017004695A MX 2017004695 A MX2017004695 A MX 2017004695A MX 2017004695 A MX2017004695 A MX 2017004695A MX 2017004695 A MX2017004695 A MX 2017004695A
Authority
MX
Mexico
Prior art keywords
liposomes
mri imaging
amyloid plaque
imaging
aromatic
Prior art date
Application number
MX2017004695A
Other languages
English (en)
Other versions
MX371295B (es
Inventor
srivastava Mayank
A Tanifum Eric
Annapragada Ananth
Original Assignee
Texas Childrens Hosptial
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Childrens Hosptial filed Critical Texas Childrens Hosptial
Publication of MX2017004695A publication Critical patent/MX2017004695A/es
Publication of MX371295B publication Critical patent/MX371295B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan compuestos aromáticos, conjugados aromático-polímero-fosfolípido que comprende los compuestos aromáticos, y las composiciones de liposoma que incluyen los conjugados aromático-polímero-fosfolípido. Las composiciones liposomales pueden ser útiles para la formación de imágenes de la enfermedad de Alzheimer, por ejemplo, la formación de imágenes de los depósitos de placa amiloide-ß característicos de la enfermedad de Alzheimer.
MX2017004695A 2014-10-08 2015-10-08 Formación de imágenes por irm de placas amiloides usando liposomas. MX371295B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462061514P 2014-10-08 2014-10-08
US201562111057P 2015-02-02 2015-02-02
PCT/US2015/054732 WO2016057812A1 (en) 2014-10-08 2015-10-08 Mri imaging of amyloid plaque using liposomes

Publications (2)

Publication Number Publication Date
MX2017004695A true MX2017004695A (es) 2018-01-24
MX371295B MX371295B (es) 2020-01-24

Family

ID=55653789

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004695A MX371295B (es) 2014-10-08 2015-10-08 Formación de imágenes por irm de placas amiloides usando liposomas.

Country Status (10)

Country Link
US (4) US9744251B2 (es)
EP (3) EP3204051B1 (es)
JP (1) JP6505235B2 (es)
KR (1) KR102409017B1 (es)
CN (1) CN107106708B (es)
AU (2) AU2015330824A1 (es)
CA (1) CA2963941C (es)
ES (2) ES2743704T3 (es)
MX (1) MX371295B (es)
WO (1) WO2016057812A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801957B2 (en) 2011-04-06 2017-10-31 Ananth Annapragada Lipid-based nanoparticles
MX366972B (es) 2012-01-20 2019-08-01 Ananth Annapragada Metodos y composiciones para caracterizar imagenes medicas en forma objetiva.
ES2743704T3 (es) 2014-10-08 2020-02-20 Texas Childrens Hospital Obtención de imágenes de IRM de la placa amiloide usando liposomas
WO2018015546A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
IL264239B (en) 2016-07-22 2022-08-01 Ac Immune Sa Compounds for imaging tau protein aggregates
CN109906090A (zh) * 2016-09-16 2019-06-18 德克萨斯州儿童医院 用于T1-MRI的新型脂质体钆(Gd)造影剂“NMRX”
EP3548002B1 (en) * 2016-11-30 2025-04-30 Texas Children's Hospital Hydrophilic fluorinated molecules for liposomal 19f mri probes with unique mr signatures
US11306089B2 (en) 2018-01-24 2022-04-19 Life Molecular Imaging Limited Gamma-carboline compounds for the detection of Tau aggregates
US20210041447A1 (en) 2018-01-24 2021-02-11 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates
CN112384202B (zh) * 2018-03-29 2023-03-21 微脉管治疗有限公司 用于检测和治疗阿尔茨海默病的组合物及方法
SG11202012150UA (en) 2018-06-08 2021-01-28 Ac Immune Sa Novel compounds for diagnosis
WO2020154623A1 (en) * 2019-01-24 2020-07-30 Alzeca Biosciences, LLC Functionalized liposomes for imaging misfolded proteins
US20210128755A1 (en) * 2019-07-08 2021-05-06 Alzeca Biosciences, LLC Targeting ligands for tau pathology
US11614451B2 (en) 2019-07-08 2023-03-28 Alzeca Biosciences, LLC Targeting ligands for tau pathology
JP7395759B2 (ja) * 2020-01-29 2023-12-11 テキサス チルドレンズ ホスピタル アミロイド沈着のｍｒｉのための標的造影剤
CN115279424A (zh) * 2020-02-12 2022-11-01 德克萨斯儿童医院 用于α-突触核蛋白沉积MRI的靶向对比剂
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition
CN115970009A (zh) * 2023-02-08 2023-04-18 丽水市中心医院 Vhpk多肽修饰的荧光纳米脂质体给药系统、其制备方法及应用
CN116869938A (zh) * 2023-07-26 2023-10-13 安徽医科大学 一种1,2,4-噁二唑-吡啶脂质体及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
ATE219688T1 (de) 1994-03-28 2002-07-15 Nycomed Imaging As Liposomen enthaltend ein röntgen- oder ultraschallkontrastmittel
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
WO2001039744A2 (en) 1999-11-30 2001-06-07 The Arizona Board Of Regents On Behalf Of The University Of Arizona Radiation sensitive liposomes
US7029655B2 (en) 2000-10-04 2006-04-18 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
WO2002094191A2 (en) 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
EP1480691A4 (en) 2002-03-05 2007-11-28 Univ State Cleveland AGGLOMERATED PARTICLES FOR THE DISPOSAL OF A MEDICINAL PRODUCT IN AEROSOL FORM
WO2004096120A2 (en) * 2003-05-01 2004-11-11 Nst Neurosurvival Technologies Ltd. Compounds that selectively bind to membranes of apoptotic cells
US7208174B2 (en) 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
EP1793868B1 (en) 2004-09-23 2010-12-29 Guerbet Liposomal contrast agents for cest imaging
CA2626005A1 (en) 2005-10-13 2007-10-25 Waratah Pharmaceuticals Inc. Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
US20070160658A1 (en) 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
US7858803B2 (en) 2007-04-27 2010-12-28 The General Hospital Corporation Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders
US20110311457A1 (en) 2007-07-26 2011-12-22 Nanoscan Imaging, Llc Methods for imaging vascular inflammation using improved nanoparticle contrast agents
CN104274840A (zh) 2007-12-05 2015-01-14 马维尔生物科学公司 纳米级对比剂和使用方法
JP5647899B2 (ja) * 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
ITMI20081052A1 (it) 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
AU2009257279A1 (en) 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
WO2010017094A2 (en) 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
CA2755998A1 (en) 2009-03-19 2010-09-23 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
ES2620177T3 (es) 2009-10-15 2017-06-27 Guerbet Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas
CA2801182A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
EP2680822B1 (en) 2011-03-02 2022-02-23 Sensulin, LLC Vesicle compositions
US9801957B2 (en) 2011-04-06 2017-10-31 Ananth Annapragada Lipid-based nanoparticles
GB201112056D0 (en) * 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
MX366972B (es) 2012-01-20 2019-08-01 Ananth Annapragada Metodos y composiciones para caracterizar imagenes medicas en forma objetiva.
US9377472B2 (en) * 2012-04-30 2016-06-28 Amoneta Diagnostics Biological complex specific for Alzheimer's disease detection in vitro and use thereof
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
ES2743704T3 (es) 2014-10-08 2020-02-20 Texas Childrens Hospital Obtención de imágenes de IRM de la placa amiloide usando liposomas

Also Published As

Publication number Publication date
EP4035688A1 (en) 2022-08-03
AU2021203388B2 (en) 2024-05-30
BR112017007238A2 (pt) 2018-01-16
US11141495B2 (en) 2021-10-12
EP3204051B1 (en) 2019-05-29
US10537649B2 (en) 2020-01-21
ES2743704T3 (es) 2020-02-20
WO2016057812A1 (en) 2016-04-14
EP4035688C0 (en) 2025-03-26
AU2015330824A1 (en) 2017-05-25
US20200069820A1 (en) 2020-03-05
AU2021203388A1 (en) 2021-06-24
US20170080111A1 (en) 2017-03-23
EP4035688B1 (en) 2025-03-26
KR102409017B1 (ko) 2022-06-16
MX371295B (es) 2020-01-24
US20160101197A1 (en) 2016-04-14
CA2963941A1 (en) 2016-04-14
JP2017532378A (ja) 2017-11-02
EP3204051A4 (en) 2018-06-27
CA2963941C (en) 2023-08-01
CN107106708A (zh) 2017-08-29
EP3204051A1 (en) 2017-08-16
ES3032054T3 (en) 2025-07-15
HK1243335A1 (zh) 2018-07-13
CN107106708B (zh) 2021-06-18
KR20170103748A (ko) 2017-09-13
US9744251B2 (en) 2017-08-29
JP6505235B2 (ja) 2019-04-24
US20200179540A1 (en) 2020-06-11
EP3542828A1 (en) 2019-09-25

Similar Documents

Publication Publication Date Title
MX371295B (es) Formación de imágenes por irm de placas amiloides usando liposomas.
IL282995A (en) Formulations of lipid nanoparticles
EP3268086A4 (en) Lsd for the treatment of alzheimer's disease
MX2017004473A (es) Formulaciones de betalactamasa y usos de las mismas.
MX2013011231A (es) Nanoparticulas basadas en lipidos.
MA46621A (fr) Traitements combinés comprenant l'administration d'imidazopyrazinones
WO2016183223A3 (en) Targeted protein contrast agents, methods of making, and uses thereof
WO2012116196A3 (en) Substituted lactosyl compounds and use thereof for cellular imaging and therapy
EP3399965A4 (en) PROLIPOSOMAL TESTOSTERONE ANDECANOATE FORMULATIONS
WO2016094374A8 (en) Compositions and methods for treatment of friedreich's ataxia
PL3285755T3 (pl) Chlorowodorek kreatyny do leczenia choroby Huntingtona
MX2016003725A (es) Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau.
IL264040A (en) An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
EP3634979A4 (en) COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS
EP3634385A4 (en) LIPOSOME PREPARATION PROCESSES INCLUDING MEDICINAL PRODUCTS
GB201615913D0 (en) Angler's seat box
EP3302579A4 (en) Iron stabilized micelles as magnetic contrast agents
IN2013MU02813A (es)
HK40050187A (en) Lipid nanoparticle formulations
HK40050182A (en) Lipid nanoparticle formulations
GB201600833D0 (en) The procedure for restoration of metabolism and new formula of 15 proteins
HK40022834B (zh) 治疗阿尔茨海默病的组合物和方法
HK40028247A (en) Methods for the preparation of liposomes comprising drugs
HK40024508A (en) Compositions and methods for treating alzheimer's disease

Legal Events

Date Code Title Description
FG Grant or registration